On Friday, Revance Therapeutics Inc (NASDAQ: RVNC) was -0.32% drop from the session before settling in for the closing price of $3.09. A 52-week range for RVNC has been $2.30 – $9.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 815.27% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 42.40%. With a float of $95.30 million, this company’s outstanding shares have now reached $104.90 million.
In an organization with 597 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 70.66%, operating margin of -67.21%, and the pretax margin is -72.59%.
Revance Therapeutics Inc (RVNC) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Revance Therapeutics Inc stocks. The insider ownership of Revance Therapeutics Inc is 8.71%, while institutional ownership is 80.74%. The most recent insider transaction that took place on Nov 18 ’24, was worth 16,296. In this transaction CMO & Global Therapeutics Lead of this company sold 3,908 shares at a rate of $4.17, taking the stock ownership to the 104,945 shares. Before that another transaction happened on Apr 16 ’24, when Company’s Chief Commercial Officer sold 2,392 for $3.80, making the entire transaction worth $9,096. This insider now owns 114,864 shares in total.
Revance Therapeutics Inc (RVNC) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 42.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.60% during the next five years compared to 0.57% growth over the previous five years of trading.
Revance Therapeutics Inc (NASDAQ: RVNC) Trading Performance Indicators
You can see what Revance Therapeutics Inc (RVNC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.92, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Revance Therapeutics Inc (RVNC)
Let’s dig in a bit further. During the last 5-days, its volume was 7.88 million. That was better than the volume of 2.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 5.17%. Additionally, its Average True Range was 0.27.
During the past 100 days, Revance Therapeutics Inc’s (RVNC) raw stochastic average was set at 8.34%, which indicates a significant increase from 5.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 113.76% in the past 14 days, which was lower than the 147.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.59, while its 200-day Moving Average is $4.45. However, in the short run, Revance Therapeutics Inc’s stock first resistance to watch stands at $3.10. Second resistance stands at $3.12. The third major resistance level sits at $3.13. If the price goes on to break the first support level at $3.07, it is likely to go to the next support level at $3.06. The third support level lies at $3.04 if the price breaches the second support level.
Revance Therapeutics Inc (NASDAQ: RVNC) Key Stats
There are 104,902K outstanding shares of the company, which has a market capitalization of 320.48 million. As of now, sales total 234,040 K while income totals -323,990 K. Its latest quarter income was 59,880 K while its last quarter net income were -38,120 K.
